News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Jones David Scott
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/10/2023 |
4
| Jones David Scott (SVP & Chief Commercial Officer) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 91,655 options to buy
@ $3.26, valued at
$298.8k
|
|
| 03/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/11/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/03/2021 |
4
| Jones David Scott (SVP & Chief Commercial Officer) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 10,000 options to buy
@ $11.47, valued at
$114.7k
|
|
| 06/23/2021 |
4
| Jones David Scott (SVP & Chief Commercial Officer) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 14,900 restricted stock units
@ $0
Granted 60,300 options to buy
@ $13.13, valued at
$791.7k
|
|
| 03/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/12/2019 |
4
| Jones David Scott (SVP & Chief Commercial Officer) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 350,000 options to buy
@ $1.47, valued at
$514.5k
|
|
| 06/12/2019 |
3
| Jones David Scott (SVP & Chief Commercial Officer) has filed a Form 3 on EyePoint Pharmaceuticals, Inc. |
|
|